原著論文

2024年刊行

1. Rieko Ohki, Koji Itahana and Tomoo Iwakuma. “The 10th International MDM2 Workshop”: Opening up new avenues for MDM2 and p53 research, the First International MDM2 Workshop in Asia. Genes to Cells, Volume 29, Issue 6: 451-455, June 2024. (https://doi.org/10.1111/gtc.13114 Published: 29 March 2024)
2. Motoyasu Tabuchi, Satoru Kikuchi, Hiroshi Tazawa, Tomohiro Okura, Toshihiro Ogawa, Ema Mitsui, Yuta Une, Shinji Kuroda, 
Hiroki Sato, Kazuhiro Noma, Shunsuke Kagawa, Toshiaki Ohara, Junko Ohtsuka, Rieko Ohki, Yasuo Urata, and Toshiyoshi Fujiwara. Functional remodeling of intraperitoneal macrophages by oncolytic adenovirus restores anti-tumor immunity for peritoneal metastasis of gastric cancer. Molecular Therapy, 20080 Volume 32, Issue 26, June 20, 2024.（https://doi.org/10.1016/j.omton.2024.200806 Published: April 23, 2024）

2023年刊行

1. Yu Chen, Tatsuki Yamamoto, Yura Takahashi, Tomoka Moro, Tomoko Tajima, Yukiko Sakaguchi, Naoaki Sakata, Akihiko Yokoyama, Susumu Hijioka, Akane Sada, Yuko Tabata and Rieko Ohki. Metabolic intervention by low carbohydrate diet suppresses the onset and progression of neuroendocrine tumors. Cell Death & Disease, 14, Article number: 597 (2023) , September 2023.

2022年刊行

1. Makoto Miyazaki, Ayaka Nakabo, Yoshiko Nagano, Yuko Nagamura, Kazuyoshi Yanagihara, Rieko Ohki, Yoshikazu Nakamura, KiyokoFukami, JunKawamoto, Kenji Umayahara, Masaru Sakamoto, Keiichi Iwaya, and Hideki Yamaguchi. Tissue factor-induced fibrinogenesis mediates cancer cell clustering and multiclonal peritoneal metastasis. Cancer Letters, available online 28 October 2022. https://doi.org/10.1016/j.canlet.2022.215983
2. Shingo Miyamoto, Yoshiko Nagano, Makoto Miyazaki, Yuko Nagamura, Kazuki Sasaki, Takeshi Kawamura, Kazuyoshi Yanagihara, Toshio Imai, Rieko Ohki, Masakazu Yashiro, Masato Tanaka, Ryuichi Sakai and Hideki Yamaguchi. Integrin α5 mediates cancer cell-fibroblast adhesion and peritoneal dissemination of diffuse-type gastric carcinoma. Cancer Letters, Vol. 526: 335-345, 1 February 2022.

2021年刊行

1. Megumi Saito, Akane Sada, Masaki Fukuyo, Kiyono Aoki, Kazuhiro Okumura, Yuko Tabata, Yu Chen, Atsushi Kaneda, Yuichi Wakabayashi and Rieko Ohki. PHLDA3 is an important downstream mediator of p53 in squamous cell carcinogenesis. Journal of Investigative Dermatology; https://doi.org/10.1016/j.jid.2021.09.007, September 2021.
2. Ylenia Capodanno, Yu Chen, Joerg Schrader, Mitsuhiro Tomosugi, Shoiciro Sumi, Akihiko Yokoyama, Nobuyoshi Hiraoka and Rieko Ohki. Cross-talk among MEN1, p53 and Notch regulates the proliferation of pancreatic neuroendocrine tumor cells by modulating INSM1 expression and subcellular localization. Neoplasia, Volume 23, Issue 9: 979-992, September 2021.
3. Yuko Nagamura, Makoto Miyazaki, Yoshiko Nagano, Arata Tomiyama, Rieko Ohki, Kazuyoshi Yanagihara, Ryuichi Sakai, and Hideki Yamaguchi. SHP2 as a Potential Therapeutic Target in Diffuse-Type Gastric Carcinoma Addicted to Receptor Tyrosine Kinase Signaling cancers. Cancers 13(17), 4309; https://doi.org/10.3390/cancers13174309, August 2021.
4. Aoze Su, Yuko Tabata, Kiyono Aoki, AkaneSada, Rieko Ohki, Satoru Nagatoishi, Kouhei Tsumoto, Siyuan Wang, Yuko Otani, and Tomohiko Ohwada. Elaboration of non-naturally occurring helical tripeptides as p53-MDM2/MDMX interaction inhibitors. Chemical and Pharmaceutical Bulletin, Vol. 69, No. 7: 681-692;  https://doi.org/10.1248/cpb.c21-00238, 2021.

2020年刊行

1. Shiori Suzuki, Shuichi Tsutsumi, Yu Chen, Chikako Ozeki, Atsushi Okabe, Tatsuya Kawase, Hiroyuki Aburatani and Rieko Ohki. Identification and characterization of the binding sequences and target genes of p53 lacking the 1st transactivation domain. Cancer Science, 111: 451-466, 2020.

2019年刊行

1. Shotaro Yamano, Makoto Kimura, Yu Chen, Naoko Imamoto and Rieko Ohki. Nuclear import of IER5 is mediated by a classical bipartite nuclear localization signal and is required for HSF1 full activation. Experimental Cell Research, Article Number: 111686, 2019. (doi: 10.1016/j.yexcr.2019.111686.)
2. Aoze Su, Siyuan Wang, Akane Sada, Yuko Otani, Luhan Zhai, Xin Liu, Misa Sayama, Rieko Ohki and Tomohiko Ohwada. Non-naturally occurring helical moleculescan interfere with p53-MDM2 and p53-MDMX protein-protein interactions. Chemical and Pharmaceutical Bulletin, Volume 67 Issue 10: 1139-1143, 2019.
3. Siyuan Wang, Yuko Otani, Luhan Zhai, Aoze Su, Masayuki Nara, Masatoshi Kawahata, Kentaro Yamaguchi, Akane Sada, Rieko Ohki, Tomohiko Ohwada. Overall Shape Constraint of Alternating /-Hybrid Peptides Containing Bicyclic Proline. Organic Letters, Manuscript No.: ol-2019-02799h (10.1021/acs.orglett.9b02799), 2019
4. Motohiro Kojima, Yu Chen, Koji Ikeda, Yuichiro Tsukada, Daigoro Takahashi, Shingo Kawano, Kota Amemiya, Masaaki Ito, Rieko Ohki, Atsushi Ochiai. Recommendation of long-term and systemic management according to the risk factors in rectal NETs patients. Scientific Reports 9(1): 2404, 2019.

2018年刊行

1. Yu Chen, Masahiro Takikawa, Shuichi Tsutsumi, Yoko Yamaguchi, Atsushi Okabe, Mayuna Shibata, Tatsuya Kawase, Akane Sada, Issei Ezawa, Yuhei Takano, Kisaburo Nagata, Yutaka Suzuki, Kentaro Semba, Hiroyuki Aburatani, Rieko Ohki. PHLDA1, another PHLDA family protein that inhibits Akt. Cancer Science, 109: 3532-3542, 2018.
2. Xiaoqi Wang, Guangyuan Li, Sanjay Koul, Rieko Ohki, Matthew Maurer, Alain Borczuk, Balazs Halmos. PHLDA2 is a key oncogene-induced negative feedback inhibitor of EGFR/ErbB2 signaling via interference with AKT signaling. Oncotarget, 9(38):24914-24926. DOI:10.18632/oncotarget.3674, 2018.
3. Junko Ohtsuka, Hiroko Oshima, Issei Ezawa, Ryo Abe, Masanobu Oshima and Rieko Ohki. Functional loss of p53 cooperates with the in vivo microenvironment to promote malignant progression of gastric cancers. Scientific Reports 8: 2291, 2018.

2017年刊行

1. Shigeyuki Magi, Kazunari Iwamoto, Noriko Yumoto, Michio Hiroshima, Takeshi Nagashima, Rieko Ohki, Amaya Garcia-Munoz, Natalia Volinsky, Alexander Von Kriegsheim, Yasushi Sako, Koichi Takahashi, Shuhei Kimura, Boris N. Kholodenko and Mariko Okada-Hatakeyama. Transcriptionally inducible Pleckstrin homology-like domain, family A, member 1, attenuates ErbB receptor activity by inhibiting receptor oligomerization. J Biol Chem, 293: 2206-2218, 2017. (doi:10.1074/jbc.M117.778399)
2. Naoaki Sakata, Yohko Yamaguchi, Yu Chen, Masayuki Shimoda, Gumpei Yoshimatsu, Michiaki Unno, Shoichiro Sumi, Rieko Ohki. Pleckstrin homology-like domain family A, member 3 (PHLDA3) deficiency improves islets engraftment through the suppression of hypoxic damage. PLoS One, 12(11): e0187927, 2017.
3. Yuki Yamamoto, Masaki Nagasato, Yosei Rin, Marina Henmi, Yoshinori Ino, Shinichi Yachida, Rieko Ohki, Nobuyoshi Hiraoka, Masatoshi Tagawa and Kazunori Aoki. Strong antitumor efficacy of a pancreatic tumor-targeting oncolytic adenovirus for neuroendocrine tumors. Cancer Medicine, 6(10): 2385-2397, 2017
4. Nakayama M, Sakai E, Echizen K, Yamada Y, Oshima H, Han TS, Ohki R, Fujii S, Ochiai A, Robine S, Voon DC, Tanaka T, Taketo MM, Oshima M. Intestinal cancer progression by mutant p53 through the acquisition of invasiveness associated with complex glandular formation. Oncogene, 19;36(42):5885-5896, 2017.

2016年刊行

1. Issei Ezawa, Yuichiro Sawai, Tatsuya Kawase, Atsushi Okabe, Shuichi Tsutsumi, Hitoshi Ichikawa, Yuka Kobayashi, Fumio Tashiro, Hideo Namiki, Tadashi Kondo, Kentaro Semba, Hiroyuki Aburatani, Yoichi Taya, Hitoshi Nakagama and Rieko Ohki. (corresponding author) A novel p53 target gene FUCA1 encodes a fucosidase and regulates growth and survival of cancer cells.  Cancer Science, 107(6):734-45, 2016.
2. Yoshinori Asano, Tatsuya Kawase, Atsushi Okabe, Shuichi Tsutsumi, Hitoshi Ichikawa, Satoko Tatebe, Issay Kitabayashi, Fumio Tashiro, Hideo Namiki, Tadashi Kondo, Kentaro Semba, Hiroyuki Aburatani, Yoichi Taya, Hitoshi Nakagama and Rieko Ohki (corresponding author). IER5 generates a novel hypo-phosphorylated active form of HSF1 and contributes to tumorigenesis. Scientific Reports, 6, 2016. (doi: 10.1038/srep19174.)

2015年刊行

1. Xiaoqi Wang, Guangyuan Li, Sanjay Koul, Rieko Ohki, Matthew Maurer, Alain Borczuk, Balazs Halmos. PHLDA2 is a key oncogene-induced negative feedback inhibitor of EGFR/ErbB2 signaling via interference with AKT signaling. Oncotarget, 2015. (doi: 10.18632/oncotarget.3674.)
2. Toshitsugu Fujita, Miyuki Yuno, Daisuke Okuzaki, Rieko Ohki, and Hodaka Fujii. Identification of non-coding RNAs associated with telomeres by enChIP-RNA-Seq. PLoS One, 10, e0123387, 2015.

2014年刊行

1. Rieko Ohki#, Kozue Saito, Yu Chen, Tatsuya Kawase, Yukie Aita, Nobuyoshi Hiraoka, Raira Saigawa, Maiko Minegishi, Goichi Yanai, Hiroko Shimizu, Shinichi Yachida, Naoaki Sakata, Akihiko Yokoyama, Ryuichiro Doi, Tomoo Kosuge, Kazuaki Shimada, Benjamin Tycko, Toshihiko Tsukada, Yae Kanai, Shoichiro Sumi, Hideo Namiki, Yoichi Taya, Tatsuhiro Shibata and Hitoshi Nakagama. (#corresponding author) PHLDA3 is a novel tumor suppressor of pancreatic neuroendocrine tumors. Proc Natl Acad Sci USA, 111 (23), E2404-E2413, 2014.　

2013年刊行

1. Toshitsugu Fujita, Yoshinori Asano, Junko Ohtsuka, Yoko Takada, Kazunobu Saito, Rieko Ohki, Hodaka Fujii. Identification of telomere-associated molecules by engineered DNA-binding molecule-mediated chromatin immunoprecipitation (enChIP). Scientific Reports, 3, doi:10.1038/srep03171, 2013. 　

2011年刊行

1. Chikako Ozeki, Tatsuhiro Shibata, Takashi Kohno, Yuichiro Sawai, Koji Okamoto, Jun Yokota, Fumio Tashiro, Seiichi Tanuma, Ryuichi Sakai, Tatsuya Kawase, Issay Kitabayashi, Yoichi Taya and Rieko Ohki#. (#corresponding author) Cancer susceptibility polymorphism of p53 at codon 72 affects phosphorylation and degradation of p53 protein. Journal of Biological Chemistry, Vol. 286, pp. 18251-18260, 2011.

2009年刊行

1. Tatsuya Kawase*, Rieko Ohki#, *, Tatsuhiro Shibata, Shuichi Tsutsumi, Naoko Kamimura, Johji Inazawa, Tsutomu Ohta, Hitoshi Ichikawa, Hiroyuki Aburatani, Fumio Tashiro and Yoichi Taya. (*These authors equally contributed to the work, #corresponding author) PH domain-only protein PHLDA3 is a p53-regulated repressor of Akt. Cell, Vol. 136, pp. 535-550, 2009.

2008年刊行

1. Tatsuya Kawase, Hitoshi Ichikawa, Tsutomu Ohta, Naohito Nozaki, Fumio Tashiro, Rieko Ohki# and Yoichi Taya#. (#corresponding author) p53 target gene AEN is an exonuclease required for p53-dependent apoptosis. Oncogene, Vol. 27, pp. 3797-810, 2008.

2007年刊行

1. Rieko Ohki*, Tatsuya Kawase*, Tsutomu Ohta, Hitoshi Ichikawa and Yoichi Taya. (*These authors equally contributed to the work) Dissecting functional roles of p53 N-terminal transactivation domains by microarray expression analysis. Cancer Science, Vol. 98, pp. 189-200, 2007.